Web Content Display Web Content Display

$detailPageBanner.getData()
Accelerating Pharmaceutical Innovation in Asia
Header Arrow

Web Content Display Web Content Display

MENARINI GROUP announces agreement with GILEAD SCIENCES to commercialize Ranexa® (ranolazine) in 50 new countries
News Corner

Web Content Display Web Content Display

Florence, Italy - 18 June 2013 – Menarini Group, the leading Italian pharmaceutical company in the world, ranking 17th in Europe and 34th in the world (IMS World Review 2012) is pleased to announce the signing of an exclusive long-term agreement with Gilead Sciences, Inc. to commercialize Ranexa® (ranolazine), an antianginal agent, in 50 new countries including China, India, Australia and New Zealand.

Menarini and Gilead are already in partnership in 68 countries in Europe, Commonwealth of Independent States (CIS) and South America. Ranexa is already commercialized by Menarini in 23 territories. In these territories, Ranexa, is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Ranexa was approved by the U.S. Food and Drug Administration in 2006 and by the European Medicine Agency in 2008.

Based on IMS 2012 data, the EU reconstructed antianginal market (C01D+C01E: only long acting nitrates) is valued at €370 million (+5% ppg) and 33 million units (-3.3% ppg) in 2012.

Commenting on the deal, Alberto Giovanni Aleotti, Vice President of Menarini Group said: "We are delighted and honored to further strengthen our long-term partnership with Gilead to help address the needs of angina patients in these new territories, in particular the Asia Pacific region."

-End-

About Menarini Group
Menarini is an international pharmaceutical company with over 16,000 employees worldwide and a presence in more than 100 countries in Europe, Asia, Latin America, Africa and the Middle East, and has a 2012 turnover of over €3 billion.

Research and internationalization represent the main areas of strategic development for its future. The Group has 14 manufacturing sites located in Italy and abroad where over 545 million packages/year are produced and distributed throughout the five continents, thus allowing Menarini to contribute to the health of patients all over the world with its high quality standards.

For more information please visit: http://www.menarini.com/

About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead, please visit the company's website at www.gilead.com.

Web Content Display Web Content Display